Top 50 Life Science Startup Investors (July 2026)

Portfolio highlights

• MixRift — MIXRIFT - game developers specialized in Mixed Reality
• unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
• Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Portfolio highlights

• Synchron — The endovascular brain computer interface.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
• HI-Bio — HI-Bio leverages human genetic and immunological insights to deliver targeted, effective medicines to patients with immune-mediated diseases.

Portfolio highlights

• Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
• Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
• Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.

Portfolio highlights

• miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
• Deep Genomics — Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.
• CREATE Medicines — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Portfolio highlights

• MDClone — The MDClone ADAMS Platform is a self-service, data analytics environment powering healthcare collaboration, innovation, and data-driven projects.
• Beijing Tianxing — Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.
• Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology

Portfolio highlights

• Cord Project — Cord is incredibly simple, incredibly fast voice messaging that lets you chat with one friend or shout to a whole group of friends. Start chatting for free on iPhone or Android now.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
• Cambridge Epigenetix — CEGX develops products for academia and industry, democratizing step-changes in accuracy and cost.

Portfolio highlights

• Vizgen — Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
• Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
• EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.

Portfolio highlights

• NextDroid — NextDroid - We're Doing Something Different
• Enact — Enact is a leading solar energy and solar software company serving homeowners, businesses, and installers. Get a free quote or request a demo today!
• ARRIS — Using next-gen advanced manufacturing technologies, ARRIS Composites produces smarter, lighter, stronger, and more sustainable products at scale.

Portfolio highlights

• Septerna — Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors
• NinePoint Medical — NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners.
• Jounce Therapeutics — Concentra is a biosciences company.

Portfolio highlights

• Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
• Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
• Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.

Portfolio highlights

• Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
• K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
• Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.

Portfolio highlights

• Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
• Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
• Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.

Portfolio highlights

• AQEMIA — Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.
• Probabl — Open Source Commons for AI, Machine Learning, and Data Science.
• Ostrea — OSTREA is a pioneering company in the creation of high-performance materials based on bio-minerals: seashells.

Portfolio highlights

• Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
• Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
• PredictImmune — Pragmatic play menciptakan demo slot x500 yang merupakan slot online gratis. Nikmati slot demo pragmatic gacor gampang menang di demo pragmatic jamin gacor.

Portfolio highlights

• Karat — Karat helps companies hire top engineering talent by improving the quality, efficiency, and equity of their technical hiring process
• Apex — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
• Flywheel.io — Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Portfolio highlights

• iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
• Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
• ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Portfolio highlights

• Arch Oncology — Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
• Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
• AGTC — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.

Portfolio highlights

• BQP — BosonQ Psi Pvt. Ltd. (BQP) is a state-of-the-art SaaS-based enterprise software venture leveraging the power of Quantum computing to speed up virtual simulations of Multiphysics and Computer-Aided Engineering (CAE) nature. BosonQ Psi is at the forefront of this quantum revolution. Our vision is to become the premier multiphysics simulation softwareusing quantum computing. Our world-class software suite will include computational science fields of fluid dynamics, structural dynamics, thermal, chemical, and aeroacoustics. With such an innovative product, we will revolutionize the computational world by enabling high-fidelity simulations that are impossible to solve with current computing technology. Further, this product will aid aerospace, automotive, energy, manufacturing, biotechnology, civil engineering, and astrophysics industries in saving millions of dollars by reducing long turnaround times of simulations used in the design process and give higher accuracy to make significant design changes for giving rise to the next generation of an electric car, eVTOL, skyscraper, or even Mars Rover.The possibility to harness the power of quantum computers is endless, and we at BQP thrive on pushing the boundaries of quantum computing technologies to serve our clients. We have made it our mission to bring these possibilities into the hands of every person - from a researcher to a scientist, from a professor to a student. Our name, BosonQ Psi, pays tribute to the great Indian physicist Dr. Satyendra Nath Bose, after whose name the elementary particle in quantum mechanics, Boson, was named and further incorporates the fundamental quantity that describes the state of the quantum particle - Psi, thus symbolizing the company's fundamental goal to contribute in India's goal to be the leader in the Quantum realm and also become a global leader in Quantum paradigm shift in coming years.
• Willow Wealth — Willow Wealth is an alternative investment platform focused on generating income streams for investors. Get exclusive access to private market investments.
• Hubble Network — Connect a Bluetooth device to a global satellite network, delivering affordable, low-power tracking and monitoring for diverse industrial and commercial applications.

Portfolio highlights

• Agility — Agility develops humanoid robots and automation platforms for warehouse, manufacturing, and logistics operations. It provides robotic deployment solutions and software platforms that support industrial automation and the handling of repetitive tasks. The company also offers software platforms to manage and support robotic operations in industrialenvironments.
• CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
• Tradeshift — Tradeshift is a supply chain network, Tradeshift is a market leader in e-invoicing and accounts payable automation and an innovator in supplier financing and B2B marketplaces.

Portfolio highlights

• AlveoGene — Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
• Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
• Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.

Portfolio highlights

• MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
• Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
• Hexigone Inhibitors — Hexigone aims to replace toxic chemicals used in the anti-corrosion market with our disruptive, novel, micro/nano reservoir technologies, creating 'smart' coatings. Our additives will enable the coatings to protect for longer in an intelligent manner, increasing the lifetime cycle of the end product, reducing the drain on primaryresources.

Portfolio highlights

• Onepot.ai — Onepot.ai offers automated synthesis of small molecules from basic building blocks using a unified, end-to-end process. It generates around fifty distinct compounds in a single workflow, eliminating the need for bespoke methods for each target. The platform employs modular couplings, deprotection, and streamlined purification steps to rapidlyassemble structurally diverse molecules. It supports chemistries that produce both sp²- and sp³-rich frameworks, enabling applications across pharmaceutical, materials, and probe development. By leveraging a catch-and-release purification protocol and iterative building-block assembly, Onepot.ai enables efficient production of complex small-molecule libraries.
• Adaption Labs — Adaptation creates AI systems that adjust to changing real-world circumstances.
• Tools For Humanity — Tools for Humanity is a technology company building for humans in the age of AI.

Portfolio highlights

• Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
• Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
• Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.

Portfolio highlights

• Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
• Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
• One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.

Portfolio highlights

• Verana Health — Verana Health is assembling the largest clinical databases in medicine to empower physicians and accelerate research for patients.
• SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
• Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.

Portfolio highlights

• Ayr Energy —
• Prosimo — Application Experience across Multi-cloud
• Empathy — Coping with the loss of a loved one is not easy. Download the Empathy App for guidance on what to expect following a loss and the tools to get you through each step.

Portfolio highlights

• iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
• Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
• Italic Health — Italic Health, Inc. is a healthcare technology company building a unified platform for managing patient data, medical billing, and insurance workflows. Its software integrates health records, appointment scheduling, and AI-driven analytics to improve care coordination, financial processes, and patient engagement.

Portfolio highlights

• Rely — Rely is a company that focuses on converting the vast amount of unstructured data found in real estate transactions into structured.
• Pocket — Pocket is an AI front office platform that automates insurance verification, patient intake / onboarding, scheduling and patient communications for rehab therapy practices (physical therapy, occupational therapy, speech therapy, chiropractic).
• Century Health — Accelerating treatments with AI-powered real-world evidence. Century Health does the heavy lifting to rapidly get you the insight you need, all while supporting the research community and protecting patient privacy.

Portfolio highlights

• OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
• Medical Informatics — Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety. The company’s Sickbay software platform enables continuous data collection from a comprehensive set of devices. Ultimately their alarm management solutions reduce alarm noise at the patient level, and send the rightalarms to care providers.Medical Informatics Corp was founded by Emma Fauss and Craig Rusin in 2010 and is based in Houston, Texas.

Portfolio highlights

• Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
• Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
• Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot

Portfolio highlights

• Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
• Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
• Gyroscope Therapeutics — Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatmentdelivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.

Portfolio highlights

• OxCan — Enabling curative cancer treatment through early detection
• 10x Science — 10x Science offers an AI software that analyzes protein data to characterize molecular structures and support biopharmaceutical research.
• Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.

Portfolio highlights

• Adimab — Premier Human Antibody Discovery and Optimization
• Kyruus Health — Kyruus Health is a care access platform that provides solutions for providers data management, patient engagement, and activation.
• Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Portfolio highlights

• Tenfold — Tenfold connects systems of engagement and customer data to enable contextual continuous conversations. Get a free demo today.
• Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
• Matik — Remove the data bottleneck & pull numbers, tables, and charts directly into decks and PDFs

Portfolio highlights

• Montai Therapeutics — Harnessing untapped diverse chemistry with AI-enabled drug discovery to develop breakthrough small molecule medicines for chronic disease.
• Foghorn Therapeutics — Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter whatour DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
• Serif Bio­med­i­cines — Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies.

Portfolio highlights

• EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
• AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
• DAMAE Medical — Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.

Portfolio highlights

• Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
• Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
• Kingsung Medical Group —

Portfolio highlights

• Ozlo Sleep — Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.
• Stateless Networks — Find a domain name today. We make it easy.
• Transparent Health Marketplace — Live draw hk tercepat situs resmi hongkong pools menyediakan hasil result hk hari ini dari siaran live hk malam ini untuk bettor toto hk live.

Portfolio highlights

• NodThera — NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.
• Logixboard — The best way for freight forwarders to give customers shipment visibility.
• Orchard Therapeutics — Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston.

Portfolio highlights

• Virti — Discover how our Immersive Learning Platform powers impactful & engaging learning experiences to transform enterprise workplace training.
• Nyobolt — Nyobolt develops high-power energy storage systems based on advanced lithium-ion battery technology designed for rapid charging and sustained high performance. The company focuses on battery systems that enable very fast energy replenishment, supporting applications where downtime needs to be minimized. Its technology combines specialized anodematerials, cell design, battery management systems, and power electronics to achieve high charge and discharge rates. The platform is used in sectors such as robotics, data centers, industrial equipment, and electric mobility where consistent high power delivery is required. It also develops integrated energy solutions that support demanding workloads like automated logistics systems and high-performance computing infrastructure. Nyobolt’s approach emphasizes optimizing cycle life, thermal stability, and energy density for repeated fast charging environments.
• Dataswyft — Infrastructure for Decentralized Data Storage, Mobility and Interoperability

Portfolio highlights

• Q32 Bio — Q32 Bio is developing drugs targeting powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.
• Contraline — Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible.
• Sagimet Biosciences — Sagimet Biosciences better reflects our expertise in fatty acid metabolism and current focus on developing ground-breaking therapeutics to treat the liver disease NASH.

Portfolio highlights

• Scopely — Scopely is an interactive entertainment and video game company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Stumble Guys”, and “Yahtzee With Buddies,” among others.Scopely creates, publishes, and live-operates immersive games that empower a directed-by-consumer™ experience.Scopely is fueled by a world-class team and a proprietary technology platform Playgami™ that supports one of the diversified portfolios in the mobile games industry. Recognized multiple times as Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has operations in more than a dozen markets across Asia-Pacific, including Bangalore and Shanghai, among others; EMEA, including Barcelona and Dublin, among others; and North America, including Boulder, Colorado, and Culver City, California, among others, with additional game studio partners across four continents.
• Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.
• Misfit Wearables — Misfit is focused on developing great wearable products: things that people would want to wear all the time for a long time. A pioneer in the emerging world of wearable sensor technology, the company is making products and services in the consumer health and fitness space to inspire people to be more active and develop healthy habits. Misfit’sfirst product is the Shine, an elegant personal activity tracker that can instantly sync with a smartphone just by placing the device on the screen. Misfit was founded in 2011 and headquartered in Burlingame, California.

Portfolio highlights

• Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 230+ centers worldwide.
• Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
• 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.

Portfolio highlights

• Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
• Aratana Therapeutics — Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercialproducts for companion animals in a cost effective and efficient manner.
• Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.

Portfolio highlights

• Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
• Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
• Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.

Portfolio highlights

• Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
• Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
• Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.

Portfolio highlights

• Adlai Nortye — Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment.
• City Therapeutics — City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• eASIC — eASIC, a fabless semiconductor company, manufactures eASIC platforms that reduce the cost of ownership and time to production of customized silicon devices. It develops Nextreme family of devices that reduce development cost and turn-around times compared to standard cell ASICs, while reducing power consumption and unit cost for designs,Nextreme-3, a fourth generation eASIC platform, and Nextreme-2, a third generation eASIC platform. eASIC also provides easicopy ASIC that provides OEMs with a path from Nextreme-3, Nextreme-2, or Nextreme devices to a cell-based easicopy ASIC, which thereby helps OEMs reduce device cost and power consumption further, or increase performance, and eZ-IP alliance program to bring a wealth of verified eASIC-ready IP cores to help customers get to market faster. Its products are used in various applications that span from wireless infrastructure to consumer handheld devices. eASIC serves customers worldwide. Zvi Or-Bach founded eASIC in 1999, with its headquarters in Santa Clara in California with additional offices worldwide.
• Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
• CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.

Portfolio highlights

• Quince Therapeutics — Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies.
• Cabaletta Bio — Cabaletta Bio discovers and develops targeted cell therapy product candidates to potentially cure patients with autoimmune diseases. Learn about our CAAR T cell products.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• Ribometrix — The Next Frontier of Drug Discovery
• G1 Therapeutics — G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.
• SpineAlign Medical — Get your very own domain easily. Fast and professional customer service.